Fibrocell to Present at 20th Annual Rodman & Renshaw Global Investment Conference
August 29, 2018 08:00 ET
|
Fibrocell Science Inc.
EXTON, Pa., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
Fibrocell Reports Second Quarter 2018 Financial Results and Recent Highlights
August 09, 2018 08:00 ET
|
Fibrocell Science Inc.
EXTON, Pa., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
Fibrocell to Host Conference Call and Webcast on Thursday, August 9, 2018 to Discuss Second Quarter 2018 Financial Results and Recent Highlights
August 02, 2018 08:00 ET
|
Fibrocell Science Inc.
EXTON, Pa., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective...
Fibrocell Announces Closing of $4.0 Million Registered Direct Offering
July 05, 2018 16:05 ET
|
Fibrocell Science Inc.
EXTON, Pa., July 05, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
Fibrocell Announces $4.0 Million Registered Direct Offering Priced At-the-Market
July 02, 2018 09:00 ET
|
Fibrocell Science Inc.
EXTON, Pa., July 02, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
Fibrocell Announces Closing of $6.0 Million Registered Direct Offering
May 31, 2018 16:05 ET
|
Fibrocell Science Inc.
EXTON, Pa., May 31, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
Fibrocell Announces $6.0 Million Registered Direct Offering Priced At-the-Market
May 29, 2018 09:20 ET
|
Fibrocell Science Inc.
EXTON, Pa., May 29, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
Fibrocell Announces One-for-Five Reverse Stock Split
May 24, 2018 08:56 ET
|
Fibrocell Science Inc
EXTON, Pa., May 24, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...
Fibrocell Reports on Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
May 21, 2018 07:00 ET
|
Fibrocell Science Inc
– FCX-007 well-tolerated up to 52 weeks post-administration – – Continued positive trends noted in wound healing and pharmacology signals, including type VII collagen expression and evidence of...
Fibrocell Announces Oral Presentation at 7th International Investigative Dermatology Meeting
May 16, 2018 16:05 ET
|
Fibrocell Science Inc
EXTON, Pa., May 16, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue...